Original Article

Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B

Volume 27 · Issue 3 · May 2016 Publish Date: May 15, 2016
Kadri Atay 1 İbrahim Hatemi 2 Billur Canbakan 3 Emine Köroğlu 4 Emre Durcan 5 Berna Yurttaş 6 İlhami Gültepe 7 Sebati Özdemir 8 Murat Tuncer 9 Abdullah Sonsuz 10
Full Text HTML
DOI

Published In

Turkish Journal of Gastroenterology

Volume 27 · Issue 3 · May 2016

Pages: 279-283

History

Published Online: May 15, 2016

Copyright © 2016 Kadri Atay, İbrahim Hatemi, Billur Canbakan, Emine Köroğlu, Emre Durcan, Berna Yurttaş, İlhami Gültepe, Sebati Özdemir, Murat Tuncer, Abdullah Sonsuz

Kadri Atay
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
İbrahim Hatemi
Departments of Gastroenterology, İstanbul University Cerrahpaşa Medical Faculty, İstanbul
Billur Canbakan
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
Emine Köroğlu
Department of Gastroenterology, Kartal Dr. Lütfi Kırdar Training and Research Hospital, İstanbul, Turkey
Emre Durcan
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
Berna Yurttaş
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
İlhami Gültepe
Department of Internal Medicine, Bezmialem Vakıf University Hospital, İstanbul, Turkey
Sebati Özdemir
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
Murat Tuncer
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
Abdullah Sonsuz
Cerrahpaşa Tıp Fakültesi İç Hastalıkları Anabilim Dalları, İstanbul
Atay, K., Hatemi, İbrahim, Canbakan, B., Köroğlu, E., Durcan, E., Yurttaş, B., … Sonsuz, A. (2016). Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B. Turkish Journal of Gastroenterology, 27(3), 279–283. https://doi.org/10.5152/tjg.2016.16085
Endnote/Zotero/Mendeley (RIS) BibTeX
Full Text Full Text PDF

Abstract

Abstract Background/Aims: Several guidelines recommend the use of tenofovir or entecavir as the first-line treatment for hepatitis B due to the lower resistance rates of these drugs than lamivudine, although lamivudine may still be preferred because of its low adverse effect profile and cost. It is important to know which patients might benefit from lamivudine as the first-line treatment. We aimed to assess the success rates of lamivudine, entecavir, and tenofovir, as well as the resistance rates, frequencies of HBsAg clearance, and risk factors for lamivudine resistance. Materials and Methods: A total of 191 patients with chronic HBeAg-negative hepatitis who were treated with lamivudine, entecavir, or tenofovir were included. Predictors of resistance to lamivudine were analyzed. Results: The cumulative first-, second-, third-, fourth-, and fifth-year rates of virologic breakthrough during extended lamivudine therapy were 24%, 30%, 38%, 46%, and 54%, respectively. The rate of undetectable DNA at the 60th month of those who took lamivudine was 51%. Cox regression analysis revealed that positive HBV DNA at the sixth month (HR=15; 95% CI: [7.1–33], p=0.001), being aged 41 years or more (HR=3.4; 95% CI: [1.8–6.4], p=0.001), and baseline HBV DNA of 170,500 IU/mL or higher (HR=2.1; 95% CI: [1.2–3.7], p=0.01) were independently associated with the development of resistance to lamivudine. Conclusion: In HBeAg-negative chronic hepatitis B, baseline serum hepatitis B virus DNA levels exceeding 170,500 IU/mL, partial virologic response in the sixth month, and age of 41 years or more were independent predictors for virologic breakthrough. Moreover, 2% of these patients cleared HBsAg.

Most read articles by the same author(s)

1 2 3 4 5 > >> 
Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 27 · Issue 3 · May 2016
Pages 279-283
DOI 10.5152/tjg.2016.16085
History
Published Online May 15, 2016
Copyright
Copyright (c) 2016 Kadri Atay, İbrahim Hatemi, Billur Canbakan, Emine Köroğlu, Emre Durcan, Berna Yurttaş, İlhami Gültepe, Sebati Özdemir, Murat Tuncer, Abdullah Sonsuz
Affiliations
1
Kadri Atay
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
2
İbrahim Hatemi
Departments of Gastroenterology, İstanbul University Cerrahpaşa Medical Faculty, İstanbul
3
Billur Canbakan
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
4
Emine Köroğlu
Department of Gastroenterology, Kartal Dr. Lütfi Kırdar Training and Research Hospital, İstanbul, Turkey
5
Emre Durcan
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
6
Berna Yurttaş
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
7
İlhami Gültepe
Department of Internal Medicine, Bezmialem Vakıf University Hospital, İstanbul, Turkey
8
Sebati Özdemir
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
9
Murat Tuncer
Department of Gastroenterology, İstanbul University Cerrahpaşa School of Medicine, İstanbul, Turkey
10
Abdullah Sonsuz
Cerrahpaşa Tıp Fakültesi İç Hastalıkları Anabilim Dalları, İstanbul
Cite this Article
Atay, K., Hatemi, İbrahim, Canbakan, B., Köroğlu, E., Durcan, E., Yurttaş, B., … Sonsuz, A. (2016). Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B. Turkish Journal of Gastroenterology, 27(3), 279–283. https://doi.org/10.5152/tjg.2016.16085
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX
Outlines